EUCTR2020-000798-26-DK进行中（未招募）1 期
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Males and females 50 to 90 years of age (inclusive) at the time of
- •informed consent.2.Diagnosis of probable Alzheimer's disease according
- •to the 2011 NIA-AA working groups criteria. Either outpatients or
- •residents of an assisted living facility, a skilled nursing home, a
- •dementia unit, or any other type of facility providing long-term
- •care.3.MMSE score between 8 and 24 at Screening and Baseline.4.Patient
- •has clinically significant, moderate-to-severe agitation for at least 2
- •weeks prior to Screening that interferes with daily routine per the
- •Investigator's judgment.5.Patients who require pharmacotherapy for the
- •treatment of agitation per the Investigator's judgment, after:•An
- •evaluation of reversible factors, and•A course of nonpharmacological
- •interventions. 6.Diagnosis of agitation must meet the International
- •Psychogeriatric Association (IPA) provisional definition of
- •agitation.7.NPI-AA total score must be = 4 at Screening and
- •Baseline.8.Patient must meet an additional predetermined blinded
- •eligibility criterion. 9.Patient has stable cardiac,pulmonary, hepatic, and
- •renal function per the Investigator's judgment. (For Germany only: The
- •eligibility of patients with non-exclusionary but abnormal/out of range
- •laboratory results will be assessed on a case-by-case basis by the
- •Investigator and Medical Monitor.The criteria below are the objective
- •non-exclusionary limits defining stable cardiac hepatic, renal,
- •hematologic, and pulmonary function at Screening and Baseline to
- •provide guidance to the Investigator and Medical Monitor) 10.No
- •clinically significant findings on the Screening ECGs based on central
- •review and on the Baseline predose ECG based on the machine read and
- •Investigator's evaluation. (per Exclusion Criterion 6). 11.Women who
- •are of childbearing potential and are sexually active must use an
- •effective method of birth control for at least 1 month prior to the
- •Baseline, during participation in the study, and for at least 30 days after
- •the last dose of study drug. The following requirements must be met: •
- •Women who are of childbearing potential must use 2 of the following
- •precautions in order to minimize the risk of failure of 1 method of birth
- •control: vasectomy, tubal ligation, vaginal diaphragm, intrauterine
- •device, birth control pills, birth control depot injection, birth control
- •implant, or condom with spermicide or sponge with spermicide. Periodic
- •abstinence, declaration of abstinence for the duration of exposure to
- •study drug, or withdrawal are not acceptable methods of contraception.•
- •Women who are sterile, postmenopausal, or practice true abstinence are
- •exempt from this requirement.•Women who are lactating, pregnant, or
- •plan to become pregnant are not eligible for participation in the study.
- •(For Germany, Denmark, and Portugal only: •Patient must be
- •postmenopausal [defined as 12 consecutive months with no menses
- •without an alternative medical cause] or surgically sterile [ie, had an
- •oophorectomy and/or hysterectomy].•Patients who are of childbearing
- •potential, lactating, pregnant, or plan to become pregnant are not
- •eligible for participation in the study.) 12.For restricted and prohibited
- •concomitant medications, patients willing and able to meet all protocol
- •requirements for duration of stability or washout prior to study entry
- •and during the study. 13.Caregiver must be willing and able to comply
- •with all study procedures, including adherence to administering study
- 另有 1 项未显示
排除标准
- •1. Caregiver is unwilling or unable, in the opinion of the Investigator, to comply with study instructions.
- •2. Patient has dementia predominantly of non-Alzheimer’s type (eg, vascular dementia, frontotemporal dementia, Parkinson’s disease, substance-induced dementia).
- •3. Patients with symptoms of agitation that are not secondary to Alzheimer’s dementia (eg, secondary to pain, other psychiatric disorder, or delirium).
- •4. Patients who have been diagnosed with an Axis 1 disorder (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision [DSM-5] criteria) including, but not limited to:
- •? Schizophrenia, schizoaffective disorder, or other psychotic disorders not related to dementia
- •? Bipolar I or II disorder, bipolar disorder not otherwise specified
- •? Current Major Depressive Episode: Patients with a history of major depressive disorder, that is currently not symptomatic, are eligible. Patients currently on a stable dose(s) of allowed antidepressant medication(s) for at least 3 months prior to the Screening visit are eligible.
- •5. Patients with myasthenia gravis (contraindication for quinidine).
- •6. Patients with any personal history of complete heart block, QTc prolongation, or torsades de pointes.
- •a. Screening and Baseline predose QT interval corrected for heart rate using the Fridericia’s formula (QTcF) of > 450 msec for males and > 470 msec for females unless due to ventricular pacing (See Section 8.1.5). Screening ECGs will be based on central review. Baseline predose ECG will be based on the machine read and Investigator’s evaluation; if the QTcF result from the machine read is exclusionary, do not administer study drug and please contact a Medical Monitor.
- •b. Presence of premature ventricular contractions (PVCs) as evaluated by a central reader and deemed clinically significant by the Investigator.
- •7. Patients with any family history of congenital QT interval prolongation syndrome.
- •8. Patients with known hypersensitivity to DM, Q, opiate drugs (codeine, etc), or any other ingredient of the study drug.
- •9. Patients who have ever received DM co-administered with Q or d6-DM co-administered with Q.
- •10. Patients who would be likely to require a prohibited concomitant medication during the study (see Table 3, Restricted and Prohibited Concomitant Medications and Appendix 1 Prohibited Concomitant Medications).
- •11. Patients with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (eg, malignancy [except skin basal cell carcinoma], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease). Certain other nonmetastatic cancer may be allowed. Each case is to be evaluated individually with a Medical Monitor.
- •12. Patients who are currently participating in or who have participated in other interventional (drug or device) clinical study, or found to be a Virtually Certain” match in Clinical Trial Subject Database (CTSdatabase) with a patient who has participated in another interventional drug or device study within 30 days of Baseline.
- •13. Patients with history of postural syncope or any history of unexplained syncope (evaluated on a case-by-case basis) within 12 months of Baseline.
- •14. Patients with a history of substance and/or alcohol abuse within 12 months of Baseline.
- •15. Patients determined to ha
研究者
相似试验
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus valganciclovir is in treating cytomegalovirus in hematopoietic stem cell transplant patientsEUCTR2015-004726-34-DETakeda Development Center Americas, Inc.550
进行中（未招募）
1 期
AVP-786 in the Treatment of Subjects with Agitation Associatedwith Dementia of the Alzheimer’s TypeAgitation Associated with Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code 10001497Term: AgitationSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-001339-38-PLOtsuka Pharmaceutical Development & Commercialization, Inc.550
进行中（未招募）
1 期
A study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type.EUCTR2020-000798-26-DEOtsuka Pharmaceutical Development & Commercialization, Inc.750
招募中
1 期
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)MedDRA version: 20.0Level: PTClassification code: 10003658Term: Atrial fibrillation Class: 100000004849Atrial FibrillationCTIS2023-503224-66-00Anthos Therapeutics Inc.1,963
进行中（未招募）
1 期
A Phase 3 study of the safety and effectiveness of Apremilast versus placebo in patients with moderate to severe plaque psoriasisPsoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease.MedDRA version: 18.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-019992-30-ATCelgene Corporation405